Background:
Coumarin and modified nitrogen heterocyclic nuclei show biological activity.
Combining these into a hybrid molecule could lead to new pharmacological agents. A series of hybrid
compounds combining coumarin and piperidine, piperazine, purine or tetrahydroisoquinoline moieties
were synthesized and evaluated for anti-arrhythmic activity.
Methods:
The Mannich reaction of coumarins (peurutenicin, peucenol and 6-cyanoumbelliferrone) with
formaldehyde and various amines, including several alkaloids – anabasine, theophylline or tetrahydroisoquinolines,
proceeds by heating under reflux in dioxane in the presence of 4-dimethylaminopyridine.
The Suzuki reaction of 6,8-disubstituted umbelliferone triflate was used for the introduction of an aryl
substituent in position 7 of the the coumarin framework.
Results:
Twenty two novel coumarin-based Mannich bases were synthesized via introduction of functional
aminomethyl group at position 8 of 6 substituted 7-hydroxy-2H-chromen-2-ones by Mannich
reaction. The results illustrated that the C-6 and C-8 substituents’ effect was obvious in our designed
system and there was a relationship between the structures and the anti-arrhythmic activity of the 6,7,8-
trisubstituted coumarins. 8-(6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-tetrahydroisoquinolinylmethyl)-
substituted peucenol derivatives shown in vivo a pronounced and selective anti-arrhythmic activity on
epinephrine arrhythmias in comparison with natural coumarin peucenol. The moderate toxicity of the
new compound encouraged further design of therapeutically relevant analogues based on this novel type
of coumarin- tetrahydroisoquinoline hybrids.
Conclusion:
We have developed a mild reaction protocol to synthesize new mannich products on the
basis of substituted coumarins. The anti-arrhythmic activity of coumarin-tetrahydroisoquinoline hybrids
was revealed. We report for the first time that coumarin containing 8-(1-(3,4,5-trimethoxyphenyl)
tetrahydroisoquinolinyl)methyl) substituent offer a suitable scaffold for the development of
novel anti-arrhythmic agents.
